Transplant atherosclerosis: role of phenotypic modulation of vascular smooth muscle by nitric oxide

R E Bundy1, N Marczin, E F Birks

  • 1Department of Cardiothoracic Surgery, National Heart & Lung Institute, Imperial College of Science Technology & Medicine, Heart Science Centre, Harefield Hospital, Middlesex, UB9 6JH, Harefield, UK.

General Pharmacology
|September 7, 2000
PubMed

Insights

Accelerated atherosclerosis in heart transplant coronary grafts is a major issue. Nitric oxide (NO) pathways critically influence vascular smooth muscle cell changes and lesion development in this condition.

Area of Science:

  • Cardiovascular Biology
  • Transplantation Immunology
  • Vascular Cell Biology

Background:

  • Occlusive accelerated atherosclerosis of coronary grafts limits heart transplant recipient longevity.
  • This vascular disease affects both epicardial and intramyocardial vessels, requiring sophisticated detection methods.
  • Accelerated atherosclerosis is multifactorial, involving initial injury, immune responses, and non-immune mechanisms.

Purpose of the Study:

  • To review recent progress on the clinical aspects and pathogenesis of accelerated atherosclerosis in heart transplantation.
  • To discuss the multifactorial contributions, including immunological and non-immunological factors.
  • To examine the role of nitric oxide (NO) in regulating vascular smooth muscle cell (VSMC) responses and lesion development.

Main Methods:

  • Review of clinical presentation and detection of accelerated atherosclerosis post-transplantation.
  • Discussion of immunological and non-immunological factors contributing to disease progression.
  • Analysis of VSMC cellular responses, phenotypic modulation, and the influence of NO signaling pathways.

Main Results:

  • Endothelium is a primary target of injury, leading to VSMC phenotypic modulation and inflammatory reactions.
  • Endogenous NO pathways regulate cellular mechanisms crucial for vessel wall structure and function.
  • NO modulates signaling pathways (MAPK, PKG, PI3K) and transcriptional events (NF-κB, AP-1) influencing VSMC behavior.

Conclusions:

  • Understanding NO's role in VSMC modulation is key to addressing accelerated atherosclerosis in heart transplants.
  • Targeting NO-regulated pathways may offer therapeutic strategies to improve graft longevity.
  • Further research into the molecular mechanisms of NO in this context is warranted.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.